BIOGEN INC. - COMMON STOCK

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 Oct 2024 10:05:33 By NetDania Notify

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

08 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 Oct 2024 12:25:18 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

03 Oct 2024 09:45:05 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

02 Oct 2024 15:08:16 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 Sep 2024 16:06:38 By NetDania Notify

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

24 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Biogen Board Appoints Two New Independent Directors

12 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

04 Sep 2024 07:30:34 By Nasdaq GlobeNewswire

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

30 Jul 2024 17:15:17 By Nasdaq GlobeNewswire

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

30 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

26 Jul 2024 07:20:38 By Nasdaq GlobeNewswire

Biogen Completes Acquisition of Human Immunology Biosciences

02 Jul 2024 09:16:51 By Nasdaq GlobeNewswire

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

27 Jun 2024 19:39:36 By Nasdaq GlobeNewswire

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

24 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

09 Jun 2024 19:37:43 By Nasdaq GlobeNewswire

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

03 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

30 May 2024 16:51:04 By Nasdaq GlobeNewswire

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

22 May 2024 07:30:00 By Nasdaq GlobeNewswire